Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

1.1K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.1K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

676
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
676
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

598
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
598
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
445
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

4.5K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study.

The Lancet. Infectious diseases·2026
Same author

Two concurrent nationwide healthcare-associated outbreaks of <i>Burkholderia cepacia</i> complex linked to product contamination, UK and Ireland, 2010-2023 - ADDENDUM.

Infection control and hospital epidemiology·2025
Same author

Understanding the impact of different hand drying methods on viral aerosols formation and surface contamination in indoor environments.

Frontiers in public health·2025
Same author

Clostridioides difficile pathogenesis and control.

Nature reviews. Microbiology·2025
Same author

Two concurrent nationwide healthcare-associated outbreaks of <i>Burkholderia cepacia</i> complex linked to product contamination, UK and Ireland, 2010-2023.

Infection control and hospital epidemiology·2025
Same author

Making Sense of Differing Guidelines for Clostridioides difficile Infection.

Infectious disease clinics of North America·2025
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Related Experiment Video

Updated: Jan 8, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.3K

Policy development for Clostridium difficile.

Mark H Wilcox1

  • 1Department of Microbiology, Leeds Teaching Hospitals NHS Trust, The General Infirmary, Old Medical School, Leeds LS1 3EX, and Leeds Institute of Molecular Medicine, University of Leeds, UK. mark.wilcox@leedsth.nhs.uk

The Journal of Antimicrobial Chemotherapy
|August 3, 2012
PubMed
Summary
This summary is machine-generated.

The Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) evaluated laboratory tests and legal requirements for Clostridium difficile infection (CDI) diagnostics. ARHAI also developed a healthcare bundle and surveillance methods for pediatric CDI.

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.9K

Related Experiment Videos

Last Updated: Jan 8, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.3K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.9K

Area of Science:

  • Infectious Diseases
  • Public Health
  • Medical Diagnostics

Background:

  • Clostridium difficile infection (CDI) incidence was high when the Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) was established.
  • Healthcare-associated infections (HAIs) pose a significant public health challenge.

Purpose of the Study:

  • To describe the multifaceted role of ARHAI in addressing CDI.
  • To outline ARHAI's contributions to laboratory diagnostics, regulatory consultation, and infection control strategies for CDI.

Main Methods:

  • Review of ARHAI's activities and initiatives related to CDI.
  • Evaluation of laboratory testing methodologies for CDI detection.
  • Consultation on regulatory compliance for in vitro diagnostic (IVD) medical devices.

Main Results:

  • ARHAI played a key role in assessing laboratory diagnostics for CDI.
  • Provided guidance on legal and regulatory requirements for CDI test manufacturers.
  • Developed a comprehensive CDI healthcare bundle and initiated surveillance programs for pediatric CDI.

Conclusions:

  • ARHAI's comprehensive approach addressed critical aspects of CDI management, from diagnostics to surveillance.
  • The committee's work contributed to controlling CDI and improving patient safety.
  • Effective strategies for laboratory testing, regulatory oversight, and infection control are crucial for managing CDI.